Executive at Adaptive Biotechnologies (ADPT) sells 5,000 shares under 10b5-1 plan

Filing Impact

(Neutral)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Adaptive Biotechnologies Corp Chief Commercial Officer, MRD, Susan Bobulsky reported an open-market sale of 5,000 shares of common stock at $19.00 per share on June 11, 2026. After this transaction, she directly holds 411,775 shares. The filing notes the trade was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 16, 2025, indicating the sale was scheduled in advance rather than timed discretionarily.

Insider Trade Summary 10b5-1

Net Seller: 5,000 shares ($95,000)

Net Sell 1 txn

Insider BOBULSKY SUSAN

Role Chief Commercial Officer, MRD

Sold 5,000 shs ($95K)

Type	Security	Shares	Price	Value
Sale	Common Stock	5,000	$19.00	$95K

Holdings After Transaction: Common Stock — 411,775 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Shares sold: 5,000 shares Sale price: $19.00 per share Shares owned after sale: 411,775 shares +2 more

5 metrics

Shares sold 5,000 shares Open-market sale on June 11, 2026

Sale price $19.00 per share Common stock transaction

Shares owned after sale 411,775 shares Direct ownership post-transaction

Transaction type Open-market sale (Code S) Non-derivative Form 4 transaction

Trading plan adoption date December 16, 2025 Rule 10b5-1 trading plan

Key Terms

Rule 10b5-1 trading plan, open-market sale, Common Stock, Form 4

4 terms

Rule 10b5-1 trading plan regulatory

"transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Common Stock financial

""security_title": "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/15/2026 - 07:13 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BOBULSKY SUSAN

(Last)

(First)

(Middle)

C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION

1165 EASTLAKE AVENUE EAST

(Street)

SEATTLE

WASHINGTON

98109

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Adaptive Biotechnologies Corp [ ADPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Commercial Officer, MRD

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/11/2026		S⁽¹⁾		5,000	D	$19	411,775	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025.

	Susan Bobulsky by Kyle Piskel, Attorney-in-Fact	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Adaptive Biotechnologies (ADPT) disclose?

Adaptive Biotechnologies disclosed that executive Susan Bobulsky sold 5,000 shares of common stock at $19.00 per share. The transaction was an open-market sale and was executed under a pre-arranged Rule 10b5-1 trading plan adopted in December 2025.

Who is Susan Bobulsky in relation to Adaptive Biotechnologies (ADPT)?

Susan Bobulsky is an officer of Adaptive Biotechnologies, serving as Chief Commercial Officer, MRD. Her Form 4 filing shows she remains a significant holder, with 411,775 shares of common stock directly owned after the reported open-market sale transaction.

How many Adaptive Biotechnologies (ADPT) shares did the executive sell and at what price?

Susan Bobulsky sold 5,000 shares of Adaptive Biotechnologies common stock at a price of $19.00 per share. The transaction was classified as an open-market sale and was reported as a non-derivative transaction in the Form 4 filing.

How many Adaptive Biotechnologies (ADPT) shares does the insider hold after this sale?

Following the 5,000-share sale, Susan Bobulsky directly holds 411,775 shares of Adaptive Biotechnologies common stock. This post-transaction figure reflects her remaining direct ownership position as reported in the Form 4 insider trading disclosure filed with regulators.

Was the Adaptive Biotechnologies (ADPT) insider sale made under a Rule 10b5-1 plan?

Yes. The Form 4 footnote states the transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by Susan Bobulsky on December 16, 2025, indicating the sale was pre-planned rather than a discretionary, opportunistic market transaction.